Publications by authors named "Yaling Xiao"

9 Publications

  • Page 1 of 1

Downregulating lncRNA NEAT1 induces proliferation and represses apoptosis of ovarian granulosa cells in polycystic ovary syndrome via microRNA-381/IGF1 axis.

J Biomed Sci 2021 Jul 15;28(1):53. Epub 2021 Jul 15.

Department of Gynecological Endocrinology and Reproduction Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 41 Damucang Hutong, Xicheng, Beijing, China.

Objective: Researchers have revealed the combined functions of long noncoding RNAs (lncRNAs) and microRNA (miRNAs) in polycystic ovary syndrome (PCOS). This study aimed to understand the role of nuclear-enriched abundant transcript 1 (NEAT1) and miR-381 involving insulin-like growth factor 1 (IGF1) in PCOS.

Methods: PCOS rat model was established by dehydroepiandrosterone induction. NEAT1, miR-381 and IGF1 expression in ovarian granulosa cells of PCOS patients and ovarian tissues of PCOS rats were tested. Bioinformatics website and dual luciferase reporter gene assay were utilized to verify the relationship between NEAT1 and miR-381 and that between miR-381 and IGF1. Levels of sex hormone, pathological changes and ovarian granulosa cell apoptosis in ovarian tissues of PCOS rats were detected. Ovarian granulosa cell proliferation and apoptosis were analyzed in vitro.

Results: NEAT1 and IGF1 expression increased while miR-381 expression decreased in the ovarian granulosa cells of patients with PCOS and the ovarian tissues of PCOS rats. In in vivo experiments, interference with NEAT1 improved the levels of sex hormones, alleviated pathological changes and suppressed ovarian granulosa cell apoptosis in the ovarian tissues of PCOS rats. In in vitro cell experiments, interference with NEAT1 suppressed apoptosis and enhanced cell proliferation of ovarian granulosa cells. NEAT1 interference-mediated effect would be reversed by up-regulating miR-381. NEAT1 acted as a ceRNA to adsorb miR-381 to target IGF1. Overexpression of IGF1 reversed the inhibitory effect of miR-381 on ovarian granulosa cell apoptosis.

Conclusion: Interference with NEAT1 increases miR-381 and reduces IGF1 levels, effectively improving the levels of sex hormones and reducing the pathological damage of ovarian tissue in rats with PCOS.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12929-021-00749-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281489PMC
July 2021

Association Between Arg72Pro Polymorphism in and Malignant Abdominal Solid Tumor Risk in Hunan Children.

Cancer Control 2021 Jan-Dec;28:10732748211004880

Department of Pediatric Surgery, Hunan Children's Hospital, Changsha, Hunan, China.

Pediatric solid tumors are heterogeneous and comprise various histological subtypes. , a tumor suppressor, orchestrates the transcriptional activation of anti-cancer genes. The gene coding for this protein is highly polymorphic, and its mutations are associated with cancer development. The Arg72Pro polymorphism in has been associated with susceptibility to various types of cancer. Here, in this hospital-based study, we evaluated the association of this polymorphism with susceptibility toward malignant abdominal solid tumors in children in the Hunan province of China. We enrolled 162 patients with neuroblastoma, 60 patients with Wilms' tumor, and 28 patients with hepatoblastoma as well as 270 controls. Genotypes were determined using a TaqMan assay, and the strength of the association was assessed using an odds ratio, within a 95% confidence interval identified using logistic regression models. Our results showed that the Arg72Pro polymorphism did not exhibit significant association with susceptibility toward pediatric malignant abdominal solid tumors. Stratification analysis revealed that this polymorphism exerts weak sex- and age-specific effects on Wilms' tumor and hepatoblastoma susceptibility, respectively. Overall, our results indicate that the Arg72Pro polymorphism may have a marginal effect on susceptibility toward pediatric malignant abdominal solid tumors in Hunan, and this finding warrants further confirmation.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/10732748211004880DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204553PMC
March 2021

Effect of the time interval between oocyte retrieval and ICSI on embryo development and reproductive outcomes: a systematic review.

Reprod Biol Endocrinol 2021 Mar 1;19(1):34. Epub 2021 Mar 1.

Department of Gynecology Endocrine and Reproductive Center, Peking Union Medical College Hospital, Peking Union Medical College/Chinese Academy of Medical Sciences, Beijing, 100730, China.

Background: Intra-cytoplasmic sperm injection (ICSI) is used in assisted reproductive technology (ART) laboratories. However, there is no consensus regarding the precise time intervals within ICSI cycles [oocyte pick up (OPU), oocyte denudation (DN), and ICSI], and results are inconsistent and contradictory. Thus, we aim to evaluate whether there is a concordance regarding the time intervals used in different laboratories and a concrete time that gives better laboratory and reproductive results.

Methods: A systematic review of the literature until July 25, 2020, was performed with the keywords "Oocyte Denudation/Denudation/Oocyte," "Intra-cytoplasmic Sperm Injection/ICSI," "Oocyte/Oocyte maturation/ cumulus," and "Cumulus removal/ removal." Articles and abstracts in English and involving human subjects referring to the effects of oocyte DN time on embryo development and clinical outcomes were included.

Results: Of the 294 evaluated articles, 24 (including 20 full articles and 4 abstracts) were included in this review. Eighteen studies analysed the effect of OPU-DN time on embryo development and clinical outcomes. Most of these studies concluded that OPU-DN time did not influence ICSI outcomes, but some suggested that oocytes should be incubated for a short time before DN to improve oocyte maturity and enhance ICSI outcomes. In addition to reports on positive or negligible effects, adverse effects were reported in 12 studies on DN-ICSI timing. Neither OPU-DN nor DN-ICSI time could improve live birth rate.

Conclusions: Oocytes should be pre-incubated for a short duration (preferably < 4 h) before DN according to the ART laboratory schedule. More randomised controlled trials are warranted to clarify the effect of DN-ICSI timing on ICSI outcomes.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12958-021-00717-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919304PMC
March 2021

The role of long noncoding RNAs in regulating invasion and metastasis of malignant tumors.

Anticancer Drugs 2020 04;31(4):319-325

Department of Pediatric Surgery, Hunan Children's Hospital, Changsha, People's Republic of China.

Long noncoding RNAs (lncRNAs) are a group of non-protein-coding transcripts exceeding 200 nucleotides in length, which are emerging as key players in various fundamental biological processes. Furthermore, it is increasingly recognized that mutation and dysregulation of lncRNAs contribute importantly to a variety of human diseases, particularly human cancers. Previous studies have revealed that altered lncRNAs have a close association with tumorigenesis, metastasis, prognosis and diagnosis of cancers. The present review aims to exhibit a brief overview of the associated reports of lncRNAs in cancers, including colorectal cancer, gastric cancer, lung adenocarcinoma, nasopharyngeal carcinoma, cervical cancer and esophageal cancer. Altogether, we argue that lncRNAs have potential as new biomarkers in cancer prognosis and diagnosis, and as promising therapeutic targets for the prevention and treatment of human cancers.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000899DOI Listing
April 2020

Melanotic neuroectodermal tumor of infancy in ovary: A rare case report.

Medicine (Baltimore) 2019 Dec;98(49):e18181

Department of Pediatric Surgery, Hunan Children's Hospital.

Rationale: Melanotic neuroectodermal tumor of infancy (MNTI) is an extremely rare benign pigmented neoplasm of neural crest origin with rapid expansile growth and a high recurrence rate. It is predominantly found in infants of <1 year of age, involvement of the head-and-neck region is the most common presentation though it is reported at other sites including mediastinum, shoulder, thigh, foot, epididymis, uterus and ovary. The patient reported here is the third case of MNTI presenting in an ovary, and the first reported in the infant ovary.

Patient Concerns: A 33-month-old girl was presented to our unit for a huge abdominal mass.

Diagnosis: MNTI was eventually diagnosed by histological manifestations supplemented with immunohistochemical findings.

Interventions: Exploratory laparotomy and complete resection were conducted successfully.

Outcomes: Postoperative course was uneventful and no recurrence was displayed in the 6-month follow-up.

Lessons: This case emphasizes that pediatric surgeons and pathologists must always consider the possibility of MNTI while dealing with ovarian neoplasms in infants. Although considered to be a benign tumor, proper treatment and close clinicoradiological follow-up of this tumor are of great importance.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000018181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6919528PMC
December 2019

gene polymorphisms and neuroblastoma susceptibility in Chinese children: a six-center case-control study.

J Cancer 2019 18;10(25):6358-6363. Epub 2019 Oct 18.

Department of Pediatric Surgery, Hunan Children's Hospital, Changsha 410004, Hunan, China.

Neuroblastoma is the most common seen solid tumor in children less than one year old. Given that polymorphisms in the lncRNA gene are observed in several types of human malignancies, there likely to be similar events that contribute to the pathogenesis of neuroblastoma. We hypothesize that single nucleotide polymorphisms (SNPs) in the gene might predispose to neuroblastoma. Here, we genotyped three SNPs (rs2839698 G>A, rs3024270 C>G, rs217727 G>A) from gene in a Chinese population (700 subjects with neuroblastoma and 1516 control subjects) enrolled from six hospitals and examined the effect of individual and combined SNPs on the risk of neuroblastoma. Odds ratios (ORs) and 95% confidence intervals (CIs) calculated from logistic regression were adopted to assess such association, adjusted for age and gender. Among them, 700 controls and 1514 cases were successfully genotyped. None of these three SNPs were found to be relevant to the risk of neuroblastoma, either in overall analysis or stratification analysis. Findings from this study excluded the participation of lncRNA gene SNPs in the risk of neuroblastoma. More independent case-control studies are encouraged to better elucidate this relationship.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.37564DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856749PMC
October 2019

rs4938723 T>C Decreases Neuroblastoma Risk: A Replication Study in the Hunan Children.

Dis Markers 2019 10;2019:6514608. Epub 2019 Sep 10.

Department of Pediatric Surgery, Hunan Children's Hospital, Changsha, 410004 Hunan, China.

Neuroblastoma is the most common seen solid neural tumor in children less than age one. As mutation in the gene is observed in several types of human malignancies, there likely to be similar events that contribute to the pathogenesis of neuroblastoma. We hypothesize that polymorphism in the gene might predispose to neuroblastoma. Here, we conducted this replication study by genotyping rs4938723 T>C from in Hunan children (162 subjects with neuroblastoma and 270 control subjects) and examined its effect on the risk of neuroblastoma. We determined such association using logistic regression, adjusted for age and gender. Relative to those with TT genotype, subjects with C allele had reduced neuroblastoma risk (TC vs. TT: adjusted OR = 0.46, 95%CI = 0.30-0.71; additive model: adjusted OR = 0.64, 95%CI = 0.47-0.88; TC/CC vs. TT: adjusted OR = 0.49, 95%CI = 0.33-0.73). Stratified analysis revealed that rs4938723 TC/CC carriers were less likely to develop neuroblastoma for patients in the subgroups of age ≤ 18 months, age > 18 months, females, males, tumors in retroperitoneal, tumors in other sites, and clinical stages II, III, IV, and III+IV. Our findings verified rs4938723 C variant allele as a protective factor for the risk of neuroblastoma. Further investigation of how rs4938723 T>C might modify neuroblastoma risk is warranted.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/6514608DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754906PMC
February 2020

Status of External Quality Assessment on Tumor Markers in China.

Clin Lab 2015 ;61(10):1383-90

Background: The nationwide external quality assessment (EQA) of tumor markers in China has been launched for years. The quality of the performance of Chinese clinical laboratories on tumor markers is partly reflected through analysis of EQA results. This report presents an 8-year EQA result of the six most common tumor markers from 2006 to 2013.

Methods: Ten freeze-dried EQA samples were distributed to participants every year. Satisfactory performance was defined as scores of more than 80% of acceptable responses with the evaluation criterion of ± 25%. The robust coefficient of variability (CV) between laboratories and percentage difference against the target value of each sample were also calculated by year.

Results: A total number of 1154 laboratories submitted results in 2013, which was more than threefold of 2006. The proportion of laboratories with satisfactory performance showed an overall rising trend over the years and was up to 95% for the second survey in 2013. The overall decrease of robust CV was observed for all analytes including alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), total prostate specific antigen (t-PSA), cancer antigen 125 (CA 125), cancer antigen 15-3 (CA 15-3), and cancer antigen 19-9 (CA 19-9) except for CEA, which exhibited a rise followed by a flat trend. The percentage difference narrowed gradually and was less than 2% in 2013.

Conclusions: The 8-year EQA results showed a significant enhancement of degree of harmonization of tumor markers in China. However, standardization among various testing systems and improvement of harmonization has yet to be achieved.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.7754/clin.lab.2015.150309DOI Listing
December 2015

Design of Analytical Run Length for Clinical Chemistry Analytes.

Clin Lab 2015 ;61(8):891-7

Background: The expected number of unacceptable patient results E (Nu) can be set as a patient-based quality goal. Analytical run length can be designed to limit E (Nu) < 1.

Methods: The new internal quality control (IQC) strategy and length of analytical run for each analyte was applied to routine IQC paralleled with the way before redesign. IQC charts were produced by QC test results to analyze and compare the performance of out-of-control error detection.

Results: Optimal analytical run lengths designed by the quality control computer software QCCS 2008 were 39 for albumin, 61 for cholesterol, 900 for triglycerides, 112 for aspartate aminotransferase, 279 for lactate dehydrogenase, 267 for alcaline phospatase, 363 for total bilirubin, 151 for ceatinine, 230 for uric acid, 46 for phosphorus PHOS, 158 for carbon dioxide, and 580 for glucose. After being redesigned, IQC strategies for ALB, CHOL, and PHOS detected more out-of-control error than before and achieved more cost-effectiveness.

Conclusions: Using E (Nu) as a QC performance measure, frequency of QC testing can be objectively designed. Additionally, new QC strategies can help find more problems of testing systems and promote efficiency and cost savings.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.7754/clin.lab.2015.141224DOI Listing
October 2015
-->